Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUKSES-B2: Olaparib plus Bevacizumab in Relapsed Small-cell Lung Cancer with DDR/Repair Pathway Alterations
KCT0006306Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib, bevacizumab in small cell lung cancer (SCLC), sponsored by AstraZeneca. Started Aug 2021; status: completed.
02
Drugs
olaparibbevacizumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on KCT0006306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0006306.